Humacyte (HUMA) News Today $2.52 +0.05 (+1.82%) As of 12:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock HUMA Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period CenterBook Partners LP Has $2.43 Million Holdings in Humacyte, Inc. (NASDAQ:HUMA)August 8 at 7:05 AM | marketbeat.comHumacyte to Present Second Quarter Financial Results and Provide Corporate Update on August 11, 2025August 7 at 8:00 AM | globenewswire.comHumacyte (HUMA) Expected to Announce Quarterly Earnings on TuesdayAugust 6 at 10:54 AM | marketbeat.comBrokerages Set Humacyte, Inc. (NASDAQ:HUMA) PT at $11.71August 4, 2025 | americanbankingnews.com200,000 Shares in Humacyte, Inc. (NASDAQ:HUMA) Bought by Pamalican Asset Management LtdAugust 3, 2025 | marketbeat.comHumacyte, Inc. (NASDAQ:HUMA) Given Consensus Rating of "Buy" by AnalystsAugust 1, 2025 | marketbeat.comHumacyte stock rises after first Symvess sale to US Military facilityJuly 25, 2025 | investing.comHumacyte shares climb 6% after first Symvess sale to U.S. military hospitalJuly 25, 2025 | msn.comHumacyte (NASDAQ:HUMA) Given "Buy" Rating at D. Boral CapitalJuly 24, 2025 | marketbeat.comHumacyte Announces First Symvess™ Sale to Military Treatment FacilityJuly 23, 2025 | globenewswire.comHumacyte (NASDAQ:HUMA) Rating Lowered to Sell at Wall Street ZenJuly 19, 2025 | marketbeat.comHumacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should KnowJuly 18, 2025 | msn.comWhy Humacyte, Inc. (HUMA) Dipped More Than Broader Market TodayJuly 15, 2025 | msn.comHumacyte Shares Climb on Symvess ECAT Listing - MorningstarJuly 10, 2025 | morningstar.comMD. Boral Capital Reaffirms Buy Rating for Humacyte (NASDAQ:HUMA)July 9, 2025 | marketbeat.comHumacyte jumps as DoD issues ECAT listing approval for SymvessJuly 9, 2025 | msn.comHumacyte stock soars after Symvess gains DOD electronic catalog listingJuly 8, 2025 | in.investing.comHumacyte Shares Climb on Symvess ECAT ListingJuly 8, 2025 | marketwatch.comHumacyte announces Symvess™ ECAT Approval from U.S. Defense Logistics AgencyJuly 8, 2025 | globenewswire.comBeat the Market the Zacks Way: Humacyte, Starbucks, Oracle in FocusJuly 7, 2025 | msn.comHumacyte, Inc. (NASDAQ:HUMA) Receives Average Rating of "Buy" from AnalystsJuly 7, 2025 | marketbeat.comHumacyte (NASDAQ:HUMA) Stock Rating Upgraded by Wall Street ZenJune 27, 2025 | marketbeat.comHumacyte, Inc. (HUMA) Stock Moves -1.79%: What You Should KnowJune 26, 2025 | msn.comHumacyte, Inc. (HUMA) Gains As Market Dips: What You Should KnowJune 18, 2025 | msn.comHumacyte (NASDAQ:HUMA) Downgraded by Wall Street Zen to SellJune 14, 2025 | marketbeat.comHumacyte: Revenue Ramp From Symvess IncomingJune 11, 2025 | seekingalpha.comCantor Fitzgerald Predicts Humacyte FY2026 EarningsJune 10, 2025 | marketbeat.comResults from Humacyte’s V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery MeetingJune 9, 2025 | theglobeandmail.comResults from Humacyte's V007 Pivotal Phase 3 AV Access Study Highlighted by Presentation at the Society for Vascular Surgery MeetingJune 9, 2025 | globenewswire.comHumacyte Paradoxically Scales Back As Symvess Begins Its Long JourneyJune 9, 2025 | seekingalpha.comHumacyte, Inc. (NASDAQ:HUMA) Short Interest Up 20.7% in MayJune 4, 2025 | marketbeat.comNuveen Asset Management LLC Lowers Stake in Humacyte, Inc. (NASDAQ:HUMA)June 4, 2025 | marketbeat.comTommy Tuberville traded these 4 stocks at the perfect time: Why they raised red flagsJune 4, 2025 | msn.comHumacyte Clinical Results in High-Risk Dialysis Patients from V007 Pivotal Phase 3June 2, 2025 | globenewswire.comHumacyte, Inc. (NASDAQ:HUMA) Shares Bought by Bank of America Corp DEJune 1, 2025 | marketbeat.comIs Humacyte, Inc. (HUMA) a Buy as Wall Street Analysts Look Optimistic?May 30, 2025 | finance.yahoo.comMillennium Management LLC Sells 348,653 Shares of Humacyte, Inc. (NASDAQ:HUMA)May 30, 2025 | marketbeat.comHumacyte, Inc. (NASDAQ:HUMA) Shares Sold by Voloridge Investment Management LLCMay 29, 2025 | marketbeat.comHumacyte, Inc. (NASDAQ:HUMA) Holdings Decreased by Two Sigma Investments LPMay 29, 2025 | marketbeat.comWaverly Advisors LLC Buys 211,009 Shares of Humacyte, Inc. (NASDAQ:HUMA)May 25, 2025 | marketbeat.comWoodline Partners LP Has $14.39 Million Holdings in Humacyte, Inc. (NASDAQ:HUMA)May 24, 2025 | marketbeat.comHumacyte, Inc. (NASDAQ:HUMA) Given Average Rating of "Buy" by AnalystsMay 20, 2025 | marketbeat.comQ3 Earnings Estimate for Humacyte Issued By HC WainwrightMay 20, 2025 | marketbeat.comHumacyte to Present at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NasdaqMay 19, 2025 | globenewswire.comHumacyte (NASDAQ:HUMA) Earns "Buy" Rating from D. Boral CapitalMay 15, 2025 | marketbeat.comEarnings call transcript: Humacyte Q1 2025 beats EPS forecast, stock surgesMay 14, 2025 | investing.comDurham firm with battered stock cuts jobs to save cashMay 14, 2025 | bizjournals.comHumacyte, Inc. (NASDAQ:HUMA) Q1 2025 Earnings Call TranscriptMay 14, 2025 | msn.comQ1 2025 Humacyte Inc Earnings CallMay 14, 2025 | finance.yahoo.comHumacyte outlines expansion of Symvess to 45 hospitals while targeting BLA submission for ATEV in dialysis by 2026May 14, 2025 | msn.com Get Humacyte News Delivered to You Automatically Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter. Email Address HUMA Media Mentions By Week HUMA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HUMA News Sentiment▼0.710.37▲Average Medical News Sentiment HUMA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HUMA Articles This Week▼510▲HUMA Articles Average Week Get Humacyte News Delivered to You Automatically Sign up to receive the latest news and ratings for HUMA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies WVE News Today EVO News Today COGT News Today ETNB News Today VERA News Today ABCL News Today CDTX News Today NTLA News Today HROW News Today CVAC News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HUMA) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Humacyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
